Integrin α6 Inhibitors
The class of Integrin α6 inhibitors encompasses a diverse array of chemical compounds designed to modulate the cellular functions of Integrin α6, a transmembrane receptor known for its involvement in cell adhesion, migration, and signal transduction. These inhibitors, whether acting directly on Integrin α6 or influencing associated pathways, play a pivotal role in unraveling the molecular intricacies of cellular responses mediated by this integrin subtype.Direct inhibitors such as TAK-285, PF-562271, Cilengitide, and VS-6063 specifically target components in the integrin signaling cascade, disrupting downstream events and altering cellular responses. For instance, TAK-285, a HER2 kinase inhibitor, indirectly impacts Integrin α6 by disrupting focal adhesion kinase (FAK) signaling, a key mediator of integrin function. PF-562271, a selective FAK inhibitor, directly affects FAK, influencing integrin-related processes. Cilengitide, a cyclic RGD peptide antagonist, interferes with integrin-mediated adhesion and migration, impacting Integrin α6-dependent functions. VS-6063, targeting FAK, disrupts integrin signaling cascades and cellular responses mediated by Integrin α6.
Other compounds, such as E7820 and GLPG0187, interact with multiple targets, including fibroblast growth factor receptors (FGFRs) and integrins. Their broad impact on signaling pathways provides insights into the intricate network governing integrin-mediated processes, indirectly influencing Integrin α6-dependent responses. Similarly, Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, affects vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs), indirectly intersecting with Integrin α6 signaling in angiogenesis and tumor microenvironment dynamics. Small molecule inhibitors like EHop-016 exhibit specific targeting of Rac GTPases and ubiquitin-specific protease 1 (USP1), respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
TAK 285 | 871026-44-7 | sc-364627 sc-364627A | 5 mg 10 mg | $405.00 $700.00 | ||
TAK-285 is a small molecule inhibitor targeting HER2 (ErbB2) kinase. By inhibiting HER2, TAK-285 disrupts downstream signaling pathways, including those involving focal adhesion kinase (FAK), which plays a role in integrin-mediated processes. This disruption can indirectly impact Integrin α6 signaling, potentially influencing cell adhesion and migration in various contexts. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271 is a potent and selective focal adhesion kinase (FAK) inhibitor. FAK is involved in integrin signaling pathways, and PF-562271's inhibition of FAK disrupts downstream signaling events. By targeting a key player in the integrin signaling cascade, PF-562271 has the potential to modulate Integrin α6-mediated cellular processes, affecting adhesion, migration, and other functions. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Cilengitide is a cyclic RGD peptide antagonist, targeting integrins including αvβ3 and αvβ5. While not specific to Integrin α6, Cilengitide's impact on integrins can influence various cellular processes. It hinders integrin-mediated adhesion and migration, potentially affecting Integrin α6-dependent functions. Its anti-angiogenic properties further highlight its role in modulating integrin-associated processes that could indirectly influence Integrin α6 signaling. | ||||||
E7820 | 289483-69-8 | sc-507333 | 10 mg | $102.00 | ||
E7820 is a multi-kinase inhibitor that targets multiple receptors, including fibroblast growth factor receptors (FGFRs). Its impact on FGFRs can influence downstream signaling pathways, potentially intersecting with Integrin α6-mediated processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with an impact on vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Its influence on VEGFRs can indirectly intersect with Integrin α6-mediated processes, particularly in angiogenesis and tumor microenvironment dynamics. | ||||||
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $78.00 | ||
EHop-016 is a selective Rac GTPase inhibitor. Rac GTPases play a role in cytoskeletal dynamics and cell migration, processes tightly regulated by integrins. By inhibiting Rac GTPases, EHop-016 can indirectly impact Integrin α6-mediated cellular responses, particularly in adhesion and migration. | ||||||